Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Accumulated Expenses: 2023-2024

Historic Accumulated Expenses for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $6.7 million.

  • Contineum Therapeutics' Accumulated Expenses rose 7.90% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 7.90%. This contributed to the annual value of $6.7 million for FY2024, which is 53.04% up from last year.
  • Per Contineum Therapeutics' latest filing, its Accumulated Expenses stood at $6.7 million for FY2024, which was up 53.04% from $4.4 million recorded in FY2023.
  • Contineum Therapeutics' Accumulated Expenses' 5-year high stood at $6.7 million during FY2024, with a 5-year trough of $4.4 million in FY2023.
  • In the last 2 years, Contineum Therapeutics' Accumulated Expenses had a median value of $5.5 million in 2023 and averaged $5.5 million.
  • Data for Contineum Therapeutics' Accumulated Expenses shows a peak YoY surged of 53.04% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Contineum Therapeutics' Accumulated Expenses stood at $4.4 million in 2023, then spiked by 53.04% to $6.7 million in 2024.